Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin extension study in advanced breast cancer
NCT00965523Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2008
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin in breast cancer, sponsored by Eisai Co., Ltd.. Started Jan 2008; status: completed.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00965523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00965523.